Supplementary Methods from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type

MLA

David G. Huntsman, et al. Supplementary Methods from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22477643.v1.

APA

David G. Huntsman, Yemin Wang, Patrick Pirrotte, Lynn Hoang, Jeffrey M. Trent, Bernard E. Weissman, C. Blake Gilks, Jessica N. McAlpine, Gregg B. Morin, Anthony Karnezis, Friedrich Kommoss, Gian Luca Negri, Shane Colborne, Christine Chow, Angela Cheng, Samuel Leung, David Farnell, Isabel N. Alcazar, Khyatiben V. Pathak, … Jennifer X. Ji. (2023). Supplementary Methods from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. https://doi.org/10.1158/1078-0432.22477643.v1

Chicago

David G. Huntsman, Yemin Wang, Patrick Pirrotte, Lynn Hoang, Jeffrey M. Trent, Bernard E. Weissman, C. Blake Gilks, et al. 2023. “Supplementary Methods from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type,” March. doi:10.1158/1078-0432.22477643.v1.